%47%6c%6f%62%61%6c%20%46%72%6f%6e%74%69%65%72%20%50%72%6f%6a%65%63%74
-
High Resolution 3D Blood Vessel Endoscope System Developed
Professor Wangyeol Oh of KAIST’s Mechanical Engineering Department has succeeded in developing an optical imaging endoscope system that employs an imaging velocity, which is up to 3.5 times faster than the previous systems. Furthermore, he has utilized this endoscope to acquire the world’s first high-resolution 3D images of the insides of in vivo blood vessel.
Professor Oh’s work is Korea’s first development of blood vessel endoscope system, possessing an imaging speed, resolution, imaging quality, and image-capture area. The system can also simultaneously perform a functional imaging, such as polarized imaging, which is advantageous for identifying the vulnerability of the blood vessel walls.
The Endoscopic Optical Coherence Tomography (OCT) System provides the highest resolution that is used to diagnose cardiovascular diseases, represented mainly by myocardial infarction.
However, the previous system was not fast enough to take images inside of the vessels, and therefore it was often impossible to accurately identify and analyze the vessel condition. To achieve an in vivo blood vessel optical imaging in clinical trials, the endoscope needed to be inserted, after which a clear liquid flows instantly, and pictures can be taken in only a few seconds.
The KAIST research team proposed a solution for such problem by developing a high-speed, high-resolution optical tomographic imaging system, a flexible endoscope with a diameter of 0.8 mm, as well as a device that can scan the imaging light within the blood vessels at high speed. Then, these devices were combined to visualize the internal structure of the vessel wall.
Using the developed system, the researchers were able to obtain high-resolution images of about 7 cm blood vessels of a rabbit’s aorta, which is similar size to human’s coronary arteries. The tomography scan took only 5.8 seconds, at a speed of 350 scans per second in all three directions with a resolution of 10~35㎛.
If the images are taken every 200 ㎛, like the currently available commercial vascular imaging endoscopes, a 7cm length vessel can be imaged in only one second.
Professor Wangyeol Oh said, “Our newly developed blood vessel endoscope system was tested by imaging a live animal’s blood vessels, which is similar to human blood vessels. The result was very successful.”
“Collaborating closely with hospitals, we are preparing to produce the imaging of an animal’s coronary arteries, which is similar in size to the human heart,” commented Professor Oh on the future clinical application and commercialization of the endoscope system. He added, “After such procedures, the technique can be applied in clinical patients within a few years.”
Professor Oh’s research was supported by the National Research Foundation of Korea and the Global Frontier Project by the Korean government. The research results were published in the 2014 January’s edition of Biomedical Optics Express.
Figure 1: End portion of optical endoscope (upper left)
Figure 2: High-speed optical scanning unit of the endoscope (top right)
Figure 3: High-resolution images of the inside of in vivo animal blood vessels (in the direction of vascular circumference and length)
Figure 4: High-resolution images of the inside of in vivo animal blood vessels (in the direction of the vein depth)
2014.03.25 View 16553 -
New BioFactory Technique Developed using sRNAs
Professor Sang Yup Lee
- published on the online edition of Nature Biotechnology. “Expected as a new strategy for the bio industry that may replace the chemical industry.”-
KAIST Chemical & Biomolecular engineering department’s Professor Sang Yup Lee and his team has developed a new technology that utilizes the synthetic small regulatory RNAs (sRNAs) to implement the BioFactory in a larger scale with more effectiveness.
* BioFactory: Microbial-based production system which creates the desired compound in mass by manipulating the genes of the cell.
In order to solve the problems of modern society, such as environmental pollution caused by the exhaustion of fossil fuels and usage of petrochemical products, an eco-friendly and sustainable bio industry is on the rise. BioFactory development technology has especially attracted the attention world-wide, with its ability to produce bio-energy, pharmaceuticals, eco-friendly materials and more.
For the development of an excellent BioFactory, selection for the gene that produces the desired compounds must be accompanied by finding the microorganism with high production efficiency; however, the previous research method had a complicated and time-consuming problem of having to manipulate the genes of the microorganism one by one.
Professor Sang Yup Lee’s research team, including Dr. Dokyun Na and Dr. Seung Min Yoo, has produced the synthetic sRNAs and utilized it to overcome the technical limitations mentioned above.
In particular, unlike the existing method, this technology using synthetic sRNAs exhibits no strain specificity which can dramatically shorten the experiment that used to take months to just a few days.
The research team applied the synthetic small regulatory RNA technology to the production of the tyrosine*, which is used as the precursor of the medicinal compound, and cadaverine**, widely utilized in a variety of petrochemical products, and has succeeded developing BioFactory with the world’s highest yield rate (21.9g /L, 12.6g / L each).
*tyrosine: amino acid known to control stress and improve concentration
**cadaverine: base material used in many petrochemical products, such as polyurethane
Professor Sang Yup Lee highlighted the significance of this research: “it is expected the synthetic small regulatory RNA technology will stimulate the BioFactory development and also serve as a catalyst which can make the chemical industry, currently represented by its petroleum energy, transform into bio industry.”
The study was carried out with the support of Global Frontier Project (Intelligent Bio-Systems Design and Synthesis Research Unit (Chief Seon Chang Kim)) and the findings have been published on January 20th in the online edition of the worldwide journal Nature Biotechnology.
2013.02.21 View 16475